LNTH INVESTOR ALERT: Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

San Diego, California--(Newsfile Corp. - October 5, 2025) - Robbins Geller Rudman & Dowd LLP announces that the Lantheus class action lawsuit – captioned Margolis v. Lantheus Holdings, Inc., No. 25-cv-07491 (S.D.N.Y.) – seeks to represent purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities and charges Lantheus as well as certain of Lantheus's executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Lantheus class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-lantheus-holdings-inc-class-action-lawsu ...

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [e-mail]. Lead plaintiff motions for the Lantheus class action lawsuit must be filed with the court no later than Monday, November 10, 2025.

CASE ALLEGATIONS: Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. According to the complaint, Lantheus's key Radiopharmaceutical Oncology product is Pylarify, a PET imaging agent used to assist in both diagnosing and subsequently treating prostate cancer.

The Lantheus class action lawsuit alleges that defendants created the false impression that they possessed reliable information pertaining to Lantheus's projected revenue outlook and anticipated growth while also minimizing risk from competition and pricing dynamics, seasonality, and macroeconomic fluctuations. In truth, according to the complaint, Lantheus's optimistic reports of Pylarify's sales growth potential and pricing normalization fell short of reality and Lantheus, despite defendants' claims, did not have an accurate understanding of the pricing and competitive dynamics of Pylarify's market.

The Lantheus class action lawsuit further alleges that on May 7, 2025, Lantheus reported its first quarter 2025 results, disclosing that Pylarify sales had decreased year-over-year due to an alleged "temporal competitive disruption." The complaint alleges that defendants further reduced their previous full-year projections due to Pylarify's shortfall, reducing the "year-over-year range to flat-to-low single-digit percent growth for the full year versus our prior view of low-single-digit to mid-single-digit growth." On this news, the price of Lantheus stock fell more than 23%, according to the complaint.